318 Results

People

  1. Motzer
    Motzer
  2. Rosenberg
    Rosenberg
  3. Hellmann
    Hellmann
  4. Rudin
    Rudin
  5. Schoenfeld
    Schoenfeld
  6. Iyer
    Iyer
  7. Ladanyi
    Ladanyi
  8. Wolchok
    Wolchok
  9. O'Cearbhaill
    O'Cearbhaill
  10. Rizvi
    Rizvi

Groups

  1. Department of Medicine (217)
  2. Solid Tumor Oncology Division (188)
  3. GSK Faculty (66)
  4. Hematologic Malignancies, Division of (65)
  5. Genitourinary Oncology Service (60)
  6. Department of Pathology and Laboratory Medicine (59)
  7. Sloan Kettering Institute Postdocs (52)
  8. Surgery (49)
  9. Thoracic Oncology (46)
  10. Weinberg Fellows (41)
  1. "programmed death 1 ligand 1"
Formats
  1. Journal Article (231)
  2. Review (46)
  3. Editorial (21)
  4. Correspondence (6)
  5. Guidelines (6)
  6. Research Letter (6)
  7. Miscellaneous (2)
Groups
  1. Department of Medicine (217)
  2. Solid Tumor Oncology Division (188)
  3. GSK Faculty (66)
  4. Hematologic Malignancies, Division of (65)
  5. Genitourinary Oncology Service (60)
  6. Department of Pathology and Laboratory Medicine (59)

More Groups

People
  1. Robert Motzer (20)
  2. Jonathan Rosenberg (16)
  3. Jedd Wolchok (15)
  4. Matthew Hellmann (14)
  5. Adam Schoenfeld (10)
  6. Charles Rudin (10)

More People

Years
  1. 2025 (25)
  2. 2024 (53)
  3. 2023 (44)
  4. 2022 (49)
  5. 2021 (29)
  6. 2020 (43)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (19)
  2. Clinical Cancer Research (17)
  3. Annals of Oncology (15)
  4. Journal of Clinical Oncology (14)
  5. Journal of Thoracic Oncology (8)
  6. New England Journal of Medicine (8)

More Publications

Publishers
  1. Elsevier Inc. (44)
  2. Nature Publishing Group (26)
  3. American Association for Cancer Research (24)
  4. Biomed Central Ltd (21)
  5. Oxford University Press (18)
  6. Elsevier Science, Inc. (17)

More Publishers

Results (318)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Local therapy for oligoprogression or consolidation in high mutational burden stage 4 colorectal cancer treated with PD-1 or PD-L1 blockade
    Journal Article

    Klemen, N. D.; Court, C. M.; Fernandes, M. C.; Walch, H. S.; Chatila, W. K.; Saadat, L. V.; Maron, S.; Crane, C.; Shia, J.; Cercek, A.; more...
    Annals of Surgical Oncology (2022)

    Fulltext@MSK | Save
  • Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial
    Journal Article

    Liu, Y.; Yao, L.; Kalhor, N.; Carter, B. W.; Altan, M.; Blumenschein, G.; Byers, L. A.; Fossella, F.; Gibbons, D. L.; Kurie, J. M.; more...
    Lung Cancer (2022)

    Fulltext@MSK | Save
  • FRACTION-RCC: Nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
    Journal Article

    Choueiri, T. K.; Kluger, H.; George, S.; Tykodi, S. S.; Kuzel, T. M.; Perets, R.; Nair, S.; Procopio, G.; Carducci, M. A.; Castonguay, V.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy
    Journal Article

    Dercle, L.; Ammari, S.; Roblin, E.; Bigorgne, A.; Champiat, S.; Taihi, L.; Plaian, A.; Hans, S.; Lakiss, S.; Tselikas, L.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial
    Journal Article

    Apolo, A. B.; Powles, T.; Escudier, B.; Burotto, M.; Zhang, J.; Simsek, B.; Scheffold, C.; Motzer, R. J.; Choueiri, T. K.
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS(G12D)-mutated non-small-cell lung cancer
    Journal Article

    Ricciuti, B.; Alessi, J. V.; Elkrief, A.; Wang, X.; Cortellini, A.; Li, Y. Y.; Vaz, V. R.; Gupta, H.; Pecci, F.; Barrichello, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
    Guidelines

    Singh, N.; Temin, S.; Baker, S. Jr.; Blanchard, E.; Brahmer, J. R.; Celano, P.; Duma, N.; Ellis, P. M.; Elkins, I. B.; Haddad, R. Y.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer
    Journal Article

    Kim, D. W.; Kim, Y. C.; Kovari, B. P.; Chung, V.; Alese, O. B.; El-Rayes, B. F.; Li, D.; Park, W.; Kim, R. D.
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Transcriptomic correlates of tumor cell PD-L1 expression and response to nivolumab monotherapy in metastatic clear cell renal cell carcinoma
    Journal Article

    Denize, T.; Hou, Y.; Pignon, J. C.; Walton, E.; West, D. J.; Freeman, G. J.; Braun, D. A.; Wu, C. J.; Gupta, S.; Motzer, R. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Clonal hematopoiesis and differential outcomes after immune checkpoint blockade
    Research Letter

    Hsiehchen, D.; Sfreddo, H. J.; Zhao, K.; Han, C. Y.; Morris, L. G. T.
    Cancer Cell (2022)

    Fulltext@MSK | Save